DCF Group clients made up 50% of top ten 2021 VC deals in MA Biotech

5 DCF clients make the 2021 list of top 10 Venture Capital Deals in Massachusetts Biotech

DCF Group proudly worked on 7 of Fierce Biotech’s 2021 “Fierce 15”

Fierce Biotech has named their 2021 “Fierce 15”, which designates the most promising early-stage biotechnology companies in the industry.

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

Biotechnology Company, Monte Rosa Therapeutics, Inc., announced the pricing of its initial public offering of 11,700,000 shares of common stock .

Tessera Therapeutics Attracts Over $230M in Series B Financing

Tessera Therapeutics announced that it has raised over $230M in Series B financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine.

Cullinan Management Announces Pricing of Upsized Initial Public Offering

Cullinan Management announced the pricing of its upsized initial public offering of 11,900,000 shares of common stock.